In this issue of Circulation,' Hori and colleagues report the results of using three antioxidant agents in an attempt to reduce ischemic injury in a coronary microembolization model. Repeated injections of 15-,um microspheres resulted in progressive microvascular obstruction, decreased function, and edema until the extent of embolization decreased flow to nearly zero (less than 0.08 ml/min/ g). In this model, adenosine release from ischemic regions induces hyperemia in nonobstructed vessels. With successive injections, progressively smaller border zones surround areas of increasing microvascular obstruction until the extent of embolization occludes See p 828 the entire bed. Pretreatment with superoxide dismutase, allopurinol, or CV3611 resulted in less edema, increased number of microspheres required for complete stoppage of flow, relatively less dysfunction during progressive embolization, and, surprisingly, increased adenosine release. Augmented adenosine release is the subject of this editorial comment; it suggests possible mechanisms for the action of antioxidants that should be explored.
Editorial Comment Adenosine
The Signal of Life? Robert L. Engler, MD In this issue of Circulation,' Hori and colleagues report the results of using three antioxidant agents in an attempt to reduce ischemic injury in a coronary microembolization model. Repeated injections of 15-,um microspheres resulted in progressive microvascular obstruction, decreased function, and edema until the extent of embolization decreased flow to nearly zero (less than 0.08 ml/min/ g). In this model, adenosine release from ischemic regions induces hyperemia in nonobstructed vessels. With successive injections, progressively smaller border zones surround areas of increasing microvascular obstruction until the extent of embolization occludes See p 828 the entire bed. Pretreatment with superoxide dismutase, allopurinol, or CV3611 resulted in less edema, increased number of microspheres required for complete stoppage of flow, relatively less dysfunction during progressive embolization, and, surprisingly, increased adenosine release. Augmented adenosine release is the subject of this editorial comment; it suggests possible mechanisms for the action of antioxidants that should be explored.
Free Radicals and Ischemia/Reperfusion Injury The beneficial effects of the three antioxidants in this nonreperfusion model add further evidence that free radicals exacerbate ischemic injury. The pioneering studies of McCord2 and Granger et a13 and subsequent investigations from many laboratories suggest that free radical production contributes to the progression of ischemia and reperfusion injury at certain critical time points. In the original hypothesis, the principal source of superoxide production during reperfusion was the metabolism of hypoxanthine to uric acid by endothelial xanthine oxidase, which was converted from xanthine dehydrogenase to xanthine oxidase by a calcium-activated protease. Under nonischemic conditions, metabolism from hypoxanthine to uric acid occurs without formation of a free radical, but the xanthine dehydrogenase-to-xanthine oxidase conversion changes the electron acceptor from nicotinamide-adenine dinucleotide to molecular oxygen. Subsequent studies have confirmed that xanthine oxidase inhibition by allopurinol, oxypurinol, or tungsten feeding may be protective, but the conclusions are controversial.45 A recent study found that a non-purine-based agent that also inhibits xanthine oxidase failed to limit reperfusion injury in a cardiovascular model, whereas oxypurinol reduced the injury under identical circumstances. This raises the question of the role of xanthine oxidase inhibition in the mechanism of protection6; perhaps oxypurinol and allopurinol have additional mechanisms of protection.
Inflammatory Reaction to Ischemia Reperfusion Two lines of investigation suggest a role for neutrophils and perhaps other inflammatory cells in ischemia/reperfusion injury. Neutropenia as well as inhibition of neutrophil endothelial adherence reduces injury in intestinal, skeletal muscle, and cardiac ischemia/reperfusion. 7 12 In the microcirculation, neutrophils are responsible for a capillary noreflow phenomenon after ischemia and reperfusion, and activated neutrophils are a major source of superoxide radicals through the NADPH oxidase system. In the broader perspective, ischemia/reperfusion injury might also be attributed to other inflammatory components such as macrophage activation, endothelial cell or neutrophil activation with the display of adherence glycoproteins, and the nonneutrophil-dependent production of potent vasoconstrictor elements by activated serum complement.13-16 Complement activation, which occurs within 15 minutes of onset of myocardial ischemia,13 also leads to the production of potent coronary vasoconstrictor agents.16 Removal of neutrophils from circulating blood attenuates this vasoconstriction. Finally, adenosine can prevent or counteract the progressive increase in the vascular resistance to collateral blood flow and high vascular resistance after reperfusion.
Adenosine
Hori et a1l found that all three agents (superoxide dismutase, allopurinol, and CV3611) increased adenosine in venous blood. Adenosine is a purine nucleoside of fundamental importance as a building block in nucleic acids, as the backbone for the energy storage-and-use system of living cells (ATP), and as a regulator of biological function. In its latter role, adenosine moderates adrenergic stimulation and inhibits inflammatory cells.17 These effects have led to the application in myocardial ischemia/reperfusion injury of a new class of pharmacological agents -the adenosine-regulating agents that augment the proportion of adenosine released from ATP catabolism.18 '19 The hypothesis is that augmented adenosine release from the breakdown of ATP is a natural defense against ischemia/reperfusion injury through several mechanisms, including vasodilation, counteracting adrenergic stimulation, inhibition of neutrophil adherence and activation, and perhaps inhibition of other inflammatory processes. Exogenously administered adenosine is protective in a variety of injury models in various organs, including skeletal muscle, intestine, heart, brain, and skin. [20] [21] [22] [23] [24] Adenosine and Oxygen Radicals in Microembolization The microvascular embolization model of myocardial ischemia used by Hori et all is quite distinct from ischemia and reperfusion; however, it has certain features that may provide insight concerning mechanisms of drug action. Progressive microvascular obstruction leads to islands of ischemia surrounded by normal myocytes. Based on the studies of Hori et al, the survival of myocytes on the border region surrounding these patchy islands of necrosis appears to be in part dependent on adenosine production, perhaps through the attendant vasodilation and hyperemia. Different from large vessel occlusion, this model results in uniform injury across the wall for which the time course has been well characterized; in common with large vessel occlusion, a role for adenosine in preserving metabolic and functional integrity has been defined.20 In the microembolization model, augmented adenosine improves function and blockade of adenosine or reduction in adenosine release worsens function, metabolism, and blood flow. 25, 26 In the recent article,' the role of free radicals was investigated by using two free radical-scavenging agents, superoxide dismutase and CV3611 and allopurinol, a pharmacological agent that inhibits xanthine dehydrogenase and xanthine oxidase. All three of these interventions resulted in improved fractional shortening, lactate extraction, myocardial oxygen consumption, and hyperemic flow through nonoccluded vessels. Thus, all three interventions appeared to either prevent or counteract vasoconstriction in microvessels adjacent to those obstructed by microspheres. What is surprising is that adenosine release from the ischemic myocardium was nearly twofold that of control with all three interventions. The adenosine receptor antagonist 8-phenyltheophylline blocked the beneficial effects of superoxide dismutase, indicating that augmented adenosine was a mechanism of action of this free radical scavenger.
Would 8-phenyltheophylline have reversed the beneficial effects of CV3611 and allopurinol as well? Is adenosine functioning as a locally acting anti-injury hormone (autocoid) in these experiments18? Could the link between reduction of free radicals and improved function be adenosine? In this particular model of progressive microvascular obstruction, adenosine could be protective of myocardial regions not yet embolized by local mechanisms similar to preconditioning. Preconditioning refers to the observation that brief periods of myocardial ischemia provide protection against subsequent ischemia/reperfusion injury. 27 The effect of preconditioning can be mimicked by adenosine agonists. Preconditioning is abolished in the presence of adenosine receptor antagonists.28 Thus, the augmented adenosine release in the presence of the three antioxidants could have a conditioning effect on neighboring microvascular regions not yet ischemic. Furthermore, preconditioning has been defined only in ischemia and reperfusion, so the relevance of that phenomenon to microembolization needs investigation. In addition, increasing adenosine release from ischemic myocardium could act as a positive feedback mechanism; the vasodilatory effects would counteract any vasoconstriction, and the antiinflammatory effects would feed back to inhibit further free radical production by PMNs. It has long been assumed that nonspecific membrane oxidation and perhaps oxidation of specific contractile-related proteins were mechanisms by which free radicals injured cells and depressed contractile function.
Is there an additional deleterious effect by which free radicals lower effective adenosine levels and thereby defeat a microvascular protective mechanism? It has been proposed that release of adenosine is the mechanism by which viable cells are recognized by cell-mediated inflammation18'19; cells that are no longer capable of ATP catabolism no longer excrete adenosine and can be recognized as necrotic debris for disposal by appropriate phagocytic cells. However, the relative role of inflammation in this model is undefined, so these mechanisms are quite speculative. Nevertheless, in the superoxide dismutase experiments, adenosine is clearly the proximate cause of increased flow and function, because these beneficial effects were specifically blocked by an adenosine receptor antagonist. Whether increased adenosine is the proximate cause of benefit with CV3611 and allopurinol remains speculative.
By what mechanism could these agents increase adenosine? Hori et all report the integrated adenosine release measured in the venous blood, which may variably reflect microvascular and interstitial adenosine levels. Could increased blood flow velocity artifactually augment adenosine release resulting from decreased degradation in the venous blood? This mechanism appears quite unlikely in dog myocardium because of the relative long half-life for adenosine in canine blood (more than 3 minutes) compared with the half-life in human blood (less than 1.5 seconds). Therefore, the results with super-Engler Adenosine oxide dismutase must truly reflect augmented microvascular adenosine concentration and possibly release. If an important mechanism of superoxide dismutase relates to augmented adenosine level, then species differences in adenosine metabolism should be considered when designing clinical applications of experimental results.
There are several other mechanisms by which decreased free radicals could account for increased adenosine. Free radicals could inhibit the natural process of adenosine production during ischemia or increase its metabolism to inosine. Adenosine-forming systems in the heart include 5'-nucleotidase and S-adenosyl homocysteine (SAH) hydrolase. Both membrane-bound and cytosol AMP-specific 5'-nucleotidases have been described. The potential for free radicals to decrease the external membrane-bound 5'-nucleotidase activity should be investigated. This might explain why extracellularly acting free radical scavengers augment venous adenosine levels. Alternately, intracellular free radicals could inhibit the SAH hydrolase enzyme that liberates adenosine from S-adenosylhomocysteine. This seems an unlikely mechanism because measured concentrations of SAH could not account for the amount of adenosine released. Other theoretical possibilities are that free radicals enhance adenosine removal by increasing the activity of adenosine deaminase, the membrane nucleoside transport system taking up adenosine, or AMP deaminase. Allopurinol or oxypurinol could also augment adenosine levels directly by altering purine catabolism. The functional importance of these possibilities is speculative.
The study reported by Hori and colleagues contains an intriguing and novel observation that during microvascular embolization, free radical scavenging by superoxide dismutase appears to exert its beneficial effect through augmented adenosine levels, and two other free radical-reducing interventions result in augmented adenosine as well. It would be worthwhile to look for similar effects of free radicalreducing interventions in more clinically relevant ischemia/reperfusion models. If these observations are confirmed in such models, then the hypothesis that adenosine can provide a link between interventions that reduce free radicals and the amelioration of ischemia/reperfusion injury should be tested. Augmenting the gain of this anti-inflammatory, antiinjury signaling system may provide clinically significant benefit in a variety of ischemic syndromes.'8 Adenosine appears to be the chemical signal that inhibits the inflammatory system from injuring viable tissue near necrotic cells. 18 The results of Hori et all suggesting that adenosine prevented inflammatory cell-activated vasoconstriction and injury in nonischemic microvascular regions are consistent with the growing body of experimental evidence supporting the hypothesis that adenosine is indeed the indicator of cell viability to inflammatory cells, the signal of life.
